Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

The initiative shifts the conversation on obesity from personal blame to scientific understanding, emphasising it as a ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...

Want a say in the news? Email Claudia at todayinpa@pennlive.com to have your thoughts on the stories covered here or on ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

A woman is speaking out after her successful attempt to buy weight-loss drug Mounjaro by using a ‘before’ image of another ...

Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for its abbreviated new drug applications for ...